Exklusiver Stryker Distributor

Joint Preservation Produkte


für die Schweiz

Screenshot 2020-05-11 at 14.18.45.png

Biocomposites announces new CE Mark for STIMULAN®

First calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue

Keele, UK, April 23 2020 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announced that its STIMULAN products have gained a new European CE mark approval for mixing with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue.

STIMULAN® targets high concentrations of antibiotic at the point of infection at levels unachievable systemically – which lowers rates of reinfection, saves costs and improves patient outcomes. The STIMULAN® Rapid Cure and STIMULAN® Kit products are the first and only calcium matrices that can carry an antibiotic into bone and soft tissue; offering surgeons the flexibility to apply a broad spectrum of ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans.

STIMULAN® is already used in over 50,000 cases every year and in thousands of hospitals around the world.

Sevika Medical AG

Sales Office

Schochenmühlestrasse 4

CH-6340 Baar


Logistic Center

Langäulistrasse 8

CH-9470 Buchs


Tel: +41 41 749 40 99

Fax: +41 41 511 22 48